Hooman Madyoon, MD
Cardiology · Los Angeles, CANPI 1285696476
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,059 of the $23,620 with a category attached, or 68.0%. It is spread thinly across 57 manufacturers, the largest accounting for just 23.0%. Reporting peaked in 2019 at $6,956 and has fallen 60.8% since, to $2,730 in 2025. Among cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $38.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$5K
- Boston Scientific$3K
- Terumo Medical Corporation$2K
- Novartis$2K
- Abbott$967
- Esperion Therapeutics, Inc.$810
- plus $10K from 51 others
What the payments were for
- Speaking & faculty fees$3,20014%
- Travel & lodging$4,33418%
- Food & beverage$16,05968%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT D Peripheral$5,164
- GlideWire$1,504
- GENERAL VASCULAR INTERVENTION$756
- ENDOCROSS Device$610
- Torus Stent Graft System$610
- Assure WCD$412
- NEXLIZET$360
- NEXLETOL$360
- FLOWTRIEVER CATHETER, S$241
- CT THROMBECTOMY SYSTEM KIT$241
- Lutonix Drug Coated Balloon$149
- Cios Alpha$147
- DIAGNOSTIC ULTRASOUND SYSTEM$147
- FFRct$131
- Artis one$130
- Carto 3$125
- PuraPly$122
- AngioJet Ultra 5000A$120
- Turbo Elite$106
- AQUADEX SMARTFLOW CONSOLE$105
How this compares
$23,620 in reported general payments places this provider in the 95th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $161,102 |
| EntrestoSacubitril/Valsartan | 72 | $88,422 |
| JardianceEmpagliflozin | 77 | $76,992 |
| Repatha SureclickEvolocumab | 111 | $64,377 |
| MounjaroTirzepatide | 48 | $47,394 |
| OzempicSemaglutide | 48 | $45,144 |
| TrulicityDulaglutide | 36 | $38,947 |
| XareltoRivaroxaban | 35 | $24,652 |
| TradjentaLinagliptin | 29 | $18,426 |
| VascepaIcosapent Ethyl | 38 | $18,156 |
| BrilintaTicagrelor | 29 | $16,755 |
| RybelsusSemaglutide | 16 | $15,492 |
| Dexlansoprazole DrDexlansoprazole | 40 | $11,392 |
| FarxigaDapagliflozin Propanediol | 15 | $9,786 |
| InpefaSotagliflozin | 16 | $9,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $350 | $161,102184 claims |
| Boehringer IngelheimJardiance, Tradjenta | $251 | $95,418106 claims |
| NovartisEntresto | $1,938 | $88,42272 claims |
| Lilly USA, LLCMounjaro, Trulicity | $182 | $86,34184 claims |
| Novo NordiskOzempic, Rybelsus | $481 | $60,63664 claims |
| AstraZenecaBrilinta, Farxiga, Crestor | $271 | $33,31458 claims |
| Johnson & JohnsonXarelto | $677 | $24,65235 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $285 | $9,25816 claims |
| BayerKerendia | $383 | $6,41211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 cardiology providers in California.
Other cardiology in Los Angeles
- Sanjay KaulLos Angeles$1.1M
- Jamshid MaddahiLos Angeles$59K
- Andrew KimLos Angeles$5K
- Shawn ShahLos Angeles$3K
- Mark UrmanLos Angeles$1K
- Hiram PalmerLos Angeles$979
- Rene PackardLos Angeles$774
- Michael WongLos Angeles$510
- Norman LeporBeverly Hills$1.9M
- Ramtin AgahMountain View$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.